1. Lenfant C.: Chest pain of cardiac and noncardiac origin. Metabolism. 2010; 59 (Suppl. 1): S41–46. doi: 10.1016/j.metabol.2010.07.014
2. Hochman J.S., Tamis J.E., Thompson T.D., et al.: Sex, clinical presentation, and outcome in patients with acute coronary syndromes. N Engl J Med. 1999; 341 (4): 226–232. doi: 10.1056/ NEJM199907223410402
3. Lanza G.A., De Vita A., Kaski J.C.: “Primary” microvascular angina: Clinical characteristics, pathogenesis and management. Interv Cardiol Rev. 2018; 13 (3): 108–111. doi: 10.15420/ icr.2018.15.2
4. Lanza G.A.: Cardiac syndrome X: A critical overview and future perspectives. Heart. 2007; 93 (2): 159–166. doi: 10.1136/hrt.2005.067330
5. Cheng T.O.: Cardiac syndrome X versus metabolic syndrome X. Int J Cardiol. 2007; 119 (2): 137–138. doi: 10.1016/j.ijcard.2006.06.062
6. Lichtlen P.R., Bargheer K., Wenzlaff P.: Long-term prognosis of patients with anginalike chest pain and normal coronary angiographic findings. J Am Coll Cardiol. 1995; 25 (5): 1013–1018. doi: 10.1016/0735-1097 (94)00519-V
7. Lamendola P., Lanza G.A., Spinelli A., et al.: Long-term prognosis of patients with cardiac syndrome X. Int J Cardiol. 2010; 140 (2): 197–199. doi: 10.1016/j.ijcard.2008.11.026
8. Di Monaco A., Lanza G.A., Bruno I., et al.: Usefulness of impairment of cardiac adrenergic nerve function to predict outcome in patients with cardiac syndrome X. Am J Cardiol. 2010; 106 (12): 1813–1818. doi: 10.1016/j.amjcard.2010.07.052
9. Singh M., Singh S., Arora R., Khosla S.: Cardiac syndrome X: Current concepts. Int J Cardiol. 2010; 142 (2): 113–119. doi: 10.1016/j.ijcard.2009.11.021
10. Ryan T.J.: The Coronary Angiogram and Its Seminal Contributions to Cardiovascular Medicine over Five Decades. Circulation. 2002; 106 (6). doi: 10.1161/01.CIR.0000024109.12658.D4
11. Kemp H.G., Vokonas P.S., Cohn P.F., Gorlin R.: The anginal syndrome associated with normal coronary arteriograms. Report of a six year experience. Am J Med. 1973; 54 (6): 735–742. doi: 10.1016/0002-9343 (73)90060-0
12. Cannon R.O., Epstein S.E.: “Microvascular angina” as a cause of chest pain with angiographically normal coronary arteries. Am J Cardiol. 1988; 61 (15): 1338–1343. doi: 10.1016/0002-9149 (88) 91180-0
13. Fox K., Alonso Garcia M.A., Ardissino D., et al.: Guidelines on the management of stable angina pectoris: Executive summary — The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J. 2006; 27 (11): 1341–1381. doi: 10.1093/eurheartj/ ehl001
14. Montalescot G., Sechtem U., Achenbach S., et al.: 2013 ESC guidelines on the management of stable coronary artery disease. Eur Heart J. 2013; 34 (38): 2949–3003. doi: 10.1093/eurheartj/eht296
15. Ong P., Camici P.G., Beltrame J.F., et al.: International standardization of diagnostic criteria for microvascular angina. Int J Cardiol. 2018; 250: 16–20. doi: 10.1016/j.ijcard.2017.08.068
16. Knuuti J., Wijns W., Achenbach S., et al.: 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020; 41 (3): 407–477. doi: 10.1093/eurheartj/ehz425
17. Diver D.J., Bier J.D., Ferreira P.E., et al.: Clinical and arteriographic characterization of patients with unstable angina without critical coronary arterial narrowing (from the TIMI-IIIA trial). Am J Cardiol. 1994; 74 (6): 531–537. doi: 10.1016/0002-9149 (94)90739-0
18. Reis S.E., Holubkov R., Smith A.J.C., et al.: Coronary microvascular dysfunction is highly prevalent in women with chest pain in the absence of coronary artery disease: Results from the NHLBI WISE study. Am Heart J. 2001; 141 (5): 735–741. doi: 10.1067/mhj.2001.114198
19. Noel Bairey Merz C., Eteiba W., Pepine C.J., Johnson B.D., Shaw L.J., Kelsey S.F.: Cardiac syndrome X: Relation to microvascular angina and other conditions. Curr Cardiovasc Risk Rep. 2007; 1 (2): 167–175. doi: 10.1007/s12170-007-0027-3
20. Bugiardini R., Merz C.N.B.: Angina with “normal” coronary arteries: A changing philosophy. J Am Med Assoc. 2005; 293 (4): 477–484. doi: 10.1001/jama.293.4.477
21. Krumholz H.M., Douglas P.S., Lauer M.S., Pasternak R.C.: Selection of patients for coronary angiography and coronary revascularization early after myocardial infarction: Is there evidence for a gender bias? Ann Intern Med. 1992; 116 (10): 785–790. doi: 10.7326/0003-4819-116-10-785
22. Kaski J.C.: Overview of gender aspects of cardiac syndrome X. Cardiovasc Res. 2002; 53 (3): 620–626. doi: 10.1016/s0008-6363 (01)00460-6
23. Pasceri V., Lanza G.A., Buffon A., Montenero A.S., Crea F., Maseri A.: Role of abnormal pain sensitivity and behavioral factors in determining chest pain in syndrome X. J Am Coll Cardiol. 1998; 31 (1): 62–66. doi: 10.1016/s0735-1097 (97)00421-x
24. Ford T.J., Stanley B., Good R., et al.: Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina: The CorMicA Trial. J Am Coll Cardiol. 2018; 72 (23): 2841–2855. doi: 10.1016/j. jacc.2018.09.006
25. Kanatsuka H., Eastham C.L., Marcus M.L., Lamping K.G.: Effects of nitroglycerin on the coronary microcirculation in normal and ischemic myocardium. J Cardiovasc Pharmacol. 1992; 19 (5): 755–763.
26. Russo G., Di Franco A., Lamendola P., et al.: Lack of effect of nitrates on exercise stress test results in patients with microvascular angina. Cardiovasc Drugs Ther. 2013; 27 (3): 229–234. doi: 10.1007/ s10557-013-6439-z
27. Ohba K., Sugiyama S., Sumida H., et al.: Microvascular coronary artery spasm presents distinctive clinical features with endothelial dysfunction as nonobstructive coronary artery disease. J Am Heart Assoc. 2012; 1 (5): e002485. doi: 10.1161/JAHA.112.002485
28. Maseri A., Crea F., Kaski J.C., Crake T.: Mechanisms of angina pectoris in syndrome X. J Am Coll Cardiol. 1991; 17 (2): 499–506. doi: 10.1016/S0735-1097 (10)80122-6
29. Lanza G.A., Crea F.: Primary coronary microvascular dysfunction: Clinical presentation, pathophysiology, and management. Circulation. 2010; 121 (21): 2317–2325. doi: 10.1161/ CIRCULATIONAHA.109.900191
30. Nihoyannopoulos P., Kaski J.C., Crake T., Maseri A.: Absence of myocardial dysfunction during stress in patients with syndrome X. J Am Coll Cardiol. 1991; 18 (6): 1463–1470. doi: 10.1016/0735- 1097 (91)90676-z
31. Panza J.A., Laurienzo J.M., Curiel R. V, et al.: Investigation of the mechanism of chest pain in patients with angiographically normal coronary arteries using transesophageal dobutamine stress echocardiography. J Am Coll Cardiol. 1997; 29 (2): 293–301. doi: 10.1016/s0735-1097 (96)00481-0
32. Ong P., Athanasiadis A., Borgulya G., Mahrholdt H., Kaski J.C., Sechtem U.: High prevalence of a pathological response to acetylcholine testing in patients with stable angina pectoris and unobstructed coronary arteries: The ACOVA study (abnormal coronary vasomotion in patients with stable angina and unobstructed coronary arteries. J Am Coll Cardiol. 2012; 59 (7): 655–662. doi: 10.1016/j.jacc.2011.11.015
33. White C.W., Wright C.B., Doty D.B., et al.: Does Visual Interpretation of the Coronary Arteriogram Predict the Physiologic Importance of a Coronary Stenosis? N Engl J Med. 1984; 310 (13): 819–824. doi: 10.1056/NEJM198403293101304
34. Hulten E., Di Carli M.F.: FFR CT : Solid PLATFORM or Thin Ice? J Am Coll Cardiol. 2015; 66 (21): 2324–2328. doi: 10.1016/j.jacc.2015.09.065
35. Thomson L.E.J., Wei J., Agarwal M., et al.: Cardiac magnetic resonance myocardial perfusion reserve index is reduced in women with coronary microvascular dysfunction: A national heart, lung, and blood institute-sponsored study from the women’s ischemia syndrome evaluation. Circ Cardiovasc Imaging. 2015; 8 (4). doi: 10.1161/CIRCIMAGING.114.002481
36. Gould K.L., Johnson N.P., Bateman T.M., et al.: Anatomic versus physiologic assessment of coronary artery disease: Role of coronary flow reserve, fractional flow reserve, and positron emission tomography imaging in revascularization decision-making. J Am Coll Cardiol. 2013; 62 (18): 1639–1653. doi: 10.1016/j.jacc.2013.07.076
37. Galiuto L., Sestito A., Barchetta S., et al.: Noninvasive Evaluation of Flow Reserve in the Left Anterior Descending Coronary Artery in Patients With Cardiac Syndrome X. Am J Cardiol. 2007; 99 (10): 1378–1383. doi: 10.1016/j.amjcard.2006.12.070
38. Lee B.K., Lim H.S., Fearon W.F., et al.: Invasive evaluation of patients with angina in the absence of obstructive coronary artery disease. Circulation. 2015; 131 (12): 1054–1060. doi: 10.1161/ CIRCULATIONAHA.114.012636
39. Ng M.K.C., Yeung A.C., Fearon W.F.: Invasive assessment of the coronary microcirculation: Superior reproducibility and less hemodynamic dependence of index of microcirculatory resistance compared with coronary flow reserve. Circulation. 2006; 113 (17): 2054–2061. doi: 10.1161/CIRCULATIO-NAHA.105.603522
40. Beltrame J.F.: Defining the coronary slow flow phenomenon. Circ J. 2012; 76 (4): 818–820. doi: 10.1253/circj.CJ-12-0205
41. Gibson C.M., Cannon C.P., Daley W.L., et al.: TIMI frame count: A quantitative method of assessing coronary artery flow. Circulation. 1996; 93 (5): 879–888. doi: 10.1161/01.CIR.93.5.879
42. Odaka Y., Takahashi J., Tsuburaya R., et al.: Plasma concentration of serotonin is a novel biomarker for coronarymicrovascular dysfunction in patients with suspected angina and unobstructive coronary arteries. Eur Heart J. 2017; 38 (7): 489–496. doi: 10.1093/eurheartj/ehw448
43. Rasmi Y., Roshani-Asl E., KhademAnsari M., SeyedMohammadza M., Rostamzadeh A.: Angiopoie-tin-2 as a biomarker for patients with Cardiac Syndrome X. J Am Coll Cardiol. 2016; 68 (16): C24. doi: 10.1016/j.jacc.2016.07.092
44. Uğurlu M., Karahan Z., Sezer F., et al.: OP-024 A Novel Biomarker in Syndrome X Disease: Mr-Proadrenomedullin. Am J Cardiol. 2016; 117: S9. doi: 10.1016/j.amjcard.2016.04.070
45. Cannon R.O. 3rd, Camici P.G., Epstein S.E.: Pathophysiological Dilemma of Syndrome X. Circulation. 1992; 85 (3): 883–892.
46. Rosano G.M., Ponikowski P., Adamopoulos S., et al.: Abnormal autonomic control of the cardiovascular system in syndrome X. Am J Cardiol. 1994; 73 (16): 1174–1179. doi: 10.1016/0002- 9149 (94)90177-5
47. Börjesson M., Albertsson P., Dellborg M., et al.: Esophageal dysfunction in syndrome X. Am J Cardiol. 1998; 82 (10): 1187–1191. doi: 10.1016/s0002-9149 (98)00598-0
48. Kao C.H., Hsieh J.F., Tsai C.S., Ho Y.J., Lee J.K.: Evidence of abnormal esophageal motility in syndrome X by radionuclide esophageal transit test. Digestion. 2000; 62 (1): 26–30. doi: 10.1159/ 000007774
49. Brunelli C., Nobili F., Spallarossa P., et al.: Cerebral blood flow reserve in patients with syndrome X. Coron Artery Dis. 1996; 7 (8): 587–590. doi: 10.1097/00019501-199608000-00005
50. Zeiher A.M., Krause T., Schächinger V., Minners J., Moser E.: Impaired endothelium-dependent vasodilation of coronary resistance vessels is associated with exercise-induced myocardial ischemia. Circulation. 1995; 91 (9): 2345–2352. doi: 10.1161/01.cir.91.9.2345
51. Lin C.-P., Lin W.-T., Leu H.-B., Wu T.-C., Chen J.-W.: Differential mononuclear cell activity and endothelial inflammation in coronary artery disease and cardiac syndrome X. Int J Cardiol. 2003; 89 (1): 53–62. doi: 10.1016/s0167-5273 (02)00428-x
52. Newby D.E., Flint L.L., Fox K.A.A., Boon N.A., Webb D.J.: Reduced responsiveness to endothelin-1 in peripheral resistance vessels of patients with syndrome X. J Am Coll Cardiol. 1998; 31 (7): 1585–1590. doi: 10.1016/S0735-1097 (98)00143-0
53. Kidawa M., Krzeminska-Pakula M., Peruga J.Z., Kasprzak J.D.: Arterial dysfunction in syndrome X: Results of arterial reactivity and pulse wave propagation tests. Heart. 2003; 89 (4): 422–426. doi: 10.1136/heart.89.4.422
54. Shmilovich H., Deutsch V., Roth A., Miller H., Keren G., George J.: Circulating endothelial progenitor cells in patients with cardiac syndrome X. Heart. 2007; 93 (9): 1071–1076. doi: 10.1136/ hrt.2005.077909
55. Trott D.W., Fadel P.J.: Inflammation as a mediator of arterial ageing. Exp Physiol. 2019; 104 (10): 1455–1471. doi: 10.1113/EP087499
56. Dollard J., Kearney P., Clarke G., Moloney G., Cryan J.F., Dinan T.G.: A prospective study of C-reactive protein as a state marker in Cardiac Syndrome X. Brain Behav Immun. 2015; 43: 27–32. doi: 10.1016/j.bbi.2014.07.011
57. Demir B., Önal B., Özyazgan S., et al.: Does Inflammation Have a Role in the Pathogenesis of Cardiac Syndrome X? A Genetic-Based Clinical Study With Assessment of Multiple Cytokine Levels. Angiology. 2015; 67 (4): 355–363. doi: 10.1177/0003319715590057
58. Recio-Mayoral A., Rimoldi O.E., Camici P.G., Kaski J.C.: Inflammation and microvascular dysfunction in cardiac syndrome X patients without conventional risk factors for coronary artery disease. JACC Cardiovasc Imaging. 2013; 6 (6): 660–667. doi: 10.1016/j.jcmg.2012.12.011
59. Recio-Mayoral A., Mason J.C., Kaski J.C., Rubens M.B., Harari O.A., Camici P.G.: Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J. 2009; 30 (15): 1837–1843. doi: 10.1093/eurheartj/ehp205
60. Konst R.E., Guzik T.J., Kaski J.C., Maas A.H.E.M., Elias-Smale S.E.: The pathogenic role of coronary microvascular dysfunction in the setting of other cardiac or systemic conditions. Cardiovasc Res. 2020; 116 (4): 817–828. doi: 10.1093/cvr/cvaa009
61. Ahmed A., Hollan I., Curran S.A., et al.: Brief Report: Proatherogenic Cytokine Microenvironment in the Aortic Adventitia of Patients with Rheumatoid Arthritis. Arthritis Rheumatol. 2016; 68 (6): 1361–1366. doi: 10.1002/art.39574
62. Karbalaei M., Sahebkar A., Keikha M.: Helicobacter pylori infection and susceptibility to cardiac syndrome X: A systematic review and meta-analysis. World J Meta-Analysis. 2021; 9 (2): 208–219. doi: 10.13105/wjma.v9.i2.208
63. Li J.J., Zhu C.G., Nan J.L., et al.: Elevated circulating inflammatory markers in female patients with cardiac syndrome X. Cytokine. 2007; 40 (3): 172–176. doi: 10.1016/j.cyto.2007.09.005
64. Tenekecioglu E., Yilmaz M., Demir S., et al.: HDL-cholesterol is associated with systemic inflammation in cardiac syndrome X. Minerva Med. 2015; 106 (3): 133–141.
65. Aslan G., Polat V., Bozcali E., Opan S., Çetin N., Ural D.: Evaluation of serum sST2 and sCD40L values in patients with microvascular angina. Microvasc Res. 2019; 122: 85–93. doi: 10.1016/j. mvr.2018.11.009
66. Akasaka T., Sueta D., Arima Y., et al.: CYP2C19 variants and epoxyeicosatrienoic acids in patients with microvascular angina. IJC Hear Vasc. 2017; 15: 15–20. doi: 10.1016/j.ijcha.2017.03.001
67. Akasaka T., Sueta D., Arima Y., et al.: Association of CYP2C19 variants and epoxyeicosatrienoic acids on patients with microvascular angina. Am J Physiol — Hear Circ Physiol. 2016; 311 (6): H1409–H1415. doi: 10.1152/ajpheart.00473.2016
68. Güler G.B., Güler E., Hatipoğlu S., et al.: Assessment of 25-OH vitamin D levels and abnormal blood pressure response in female patients with cardiac syndrome X. Anatol J Cardiol. 2016; 16 (12): 961–966. doi: 10.14744/AnatolJCardiol.2016.6862
69. Horváth Z., Csuka D., Vargova K., et al.: Elevated C1rC1sC1inh levels independently predict atherosclerotic coronary heart disease. Mol Immunol. 2013; 54 (1): 8–13. doi: 10.1016/j. molimm.2012.10.033
70. Horváth Z., Csuka D., Vargova K., et al.: Association of Low Ficolin-Lectin Pathway Parameters with Cardiac Syndrome X. Scand J Immunol. 2016; 84 (3): 174–181. doi: 10.1111/sji.12454
71. Cenko E., Amaduzzi P.L., Bugiardini R.: Microvascular angina as a cause of ischemia: An update. In: Gender Differences in the Pathogenesis and Management of Heart Disease. Springer International Publishing; 2018: 135–163. doi: 10.1007/978-3-319-71135-5_9
72. Kaski J.C.: Cardiac syndrome X in women: The role of oestrogen deficiency. Heart. 2006; 92 (Suppl. 3): 5–9. doi: 10.1136/hrt.2005.070318
73. Gilligan D.M., Badar D.M., Panza J.A., Quyyumi A.A., Cannon R.O.: Acute vascular effects of estrogen in postmenopausal women. Circulation. 1994; 90 (2): 786–791. doi: 10.1161/01. CIR.90.2.786
74. Lim T.K., Choy A.J., Khan F., Belch J.J., Struthers A.D., Lang C.C.: Therapeutic development in cardiac syndrome X: A Need to target the underlying pathophysiology: REVIEW. Cardiovasc Ther. 2009; 27 (1): 49–58. doi: 10.1111/j.1755-5922.2008.00070.x
75. Opherk D., Mall G., Zebe H., et al.: Reduction of coronary reserve: a mechanism for angina pectoris in patients with arterial hypertension and normal coronary arteries. Circulation. 1984; 69 (1): 1–7. doi: 10.1161/01.CIR.69.1.1
76. Meeder J.G., Blanksma P.K., Crijns H.J.G.M., et al.: Mechanisms of angina pectoris in syndrome X assessed by myocardial perfusion dynamics and heart rate variability. Eur Heart J. 1995; 16 (11): 1571–1577. doi: 10.1093/oxfordjournals.eurheartj.a060780
77. Saghari M., Assadi M., Eftekhari M., et al.: Frequency and severity of myocardial perfusion abnormalities using Tc-99m MIBI SPECT in cardiac syndrome X. BMC Nucl Med. 2006; 6: 1–8. doi: 10.1186/1471-2385-6-1
78. Kaski J.C., Rosano G.M.C., Collins P., Nihoyannopoulos P., Maseri A., Poole-Wilson P.A.: Cardiac syndrome X: Clinical characteristics and left ventricular function. Long-term follow-up study. J Am Coll Cardiol. 1995; 25 (4): 807–814. doi: 10.1016/0735-1097 (94)00507-M
79. Furgała A., Kolasińska-Kloch W., Kloch M., Laskiewicz J., Thor P.J.: Heart rate variability in cardiological syndrome X patients | Zmienność rytmu serca u chorych z kardiologicznym zespołem X. Folia Cardiol. 2003; 10 (4).
80. Adamopoulos S., Rosano G.M., Ponikowski P., et al.: Impaired baroreflex sensitivity and sympathovagal balance in syndrome X. Am J Cardiol. 1998; 82 (7): 862–868. doi: 10.1016/s0002- 9149 (98)00493-7
81. Crea F., Camici P.G., Merz C.N.B.: Coronary microvascular dysfunction: An update. Eur Heart J. 2014; 35 (17): 1101–1111. doi: 10.1093/eurheartj/eht513
82. Chen J.W., Hsu N.W., Ting C.T., Lin S.J., Chang M.S.: Differential coronary hemodynamics and left ventricular contractility in patients with syndrome X. Int J Cardiol. 2000; 75 (1): 49–57. doi: 10.1016/ s0167-5273 (00)00285-0
83. Mammana C., Salomone O.A., Kautzner J., Schwartzman R.A., Kaski J.C.: Heart rate-independent prolongation of QTc interval in women with syndrome X. Clin Cardiol. 1997; 20 (4): 357–360. doi: 10.1002/clc.4960200411
84. Gulli G., Cemin R., Pancera P., Menegatti G., Vassanelli C., Cevese A.: Evidence of parasympathetic impairment in some patients with cardiac syndrome X. Cardiovasc Res. 2001; 52 (2): 208–216. doi: 10.1016/S0008-6363 (01)00369-8
85. Antonio L.G., Alessandro G., Christian P., et al.: Abnormal Cardiac Adrenergic Nerve Function in Patients With Syndrome X Detected By [123I]Metaiodobenzylguanidine Myocardial Scintigraphy. Circulation. 1997; 96 (3): 821–826. doi: 10.1161/01.CIR.96.3.821
86. Lee W.L., Chen J.-W.W., Kong C.W., et al.: Changes in Cardiac Autonomic Activities in Patients with Syndrome X: A Study of Spectral Analysis of Heart Rate Variability. Angiology. 1996; 47 (10): 929–939. doi: 10.1177/000331979604701001
87. Eriksson B., Jansson E., Kaijser L., Sylvan C.: Exercise performance, autonomic control and skeletal muscle function in syndrome X. Circulation. 1997; 96 (8S).
88. Rosano G.M., Kaski J.C., Arie S., et al.: Failure to demonstrate myocardial ischaemia in patients with angina and normal coronary arteries. Evaluation by continuous coronary sinus pH monitoring and lactate metabolism. Eur Heart J. 1996; 17 (8): 1175–1180. doi: 10.1093/oxfordjournals.eurheartj. a015034
89. Bøtker H.E., Sonne H.S., Frøbert O., Andreasen F.: Enhanced exercise-induced hyperkalemia in patients with syndrome X. J Am Coll Cardiol. 1999; 33 (4): 1056–1061. doi: 10.1016/S0735-1097(98) 00683-4
90. Villasante Fricke A.C., Iacobellis G.: Epicardial Adipose Tissue: Clinical Biomarker of Cardio- Metabolic Risk. Int J Mol Sci. 2019; 20 (23). doi: 10.3390/ijms20235989
91. Kalçik M., Yesin M., Güner A., et al.: Echocardiographic measurement of epicardial adipose tissue thickness in patients with microvascular angina. Interv Med Appl Sci. 2019; 11 (2): 106–111. doi: 10.1556/1646.11.2019.12
92. Lanza G.A., Colonna G., Pasceri V., Maseri A.: Atenolol versus amlodipine versus isosorbide-5- mononitrate on anginal symptoms in syndrome X. Am J Cardiol. 1999; 84 (7): 854–856. doi: 10.1016/S0002-9149 (99)00450-6
93. Leonardo F., Fragasso G., Rossetti E., et al.: Comparison of trimetazidine with atenolol in patients with syndrome X: effects on diastolic function and exercise tolerance. Cardiologia. 1999; 44 (12): 1065–1069.
94. Erdamar H., Sen N., Tavil Y., et al.: The effect of nebivolol treatment on oxidative stress and antioxidant status in patients with cardiac syndrome-X. Coron Artery Dis. 2009; 20 (3): 238–244. doi: 10.1097/MCA.0b013e32830936bb
95. Ozçelik F., Altun A., Ozbay G.: Antianginal and anti-ischemic effects of nisoldipine and ramipril in patients with syndrome X. Clin Cardiol. 1999; 22 (5): 361–365. doi: 10.1002/clc.4960220513
96. Zhang X., Li Q., Zhao J., et al.: Effects of combination of statin and calcium channel blocker in patients with cardiac syndrome X. Coron Artery Dis. 2014; 25 (1): 40–44. doi: 10.1097/ MCA.0000000000000054
97. Ong P., Athanasiadis A., Sechtem U.: Pharmacotherapy for coronary microvascular dysfunction. Eur Hear J — Cardiovasc Pharmacother. 2015; 1 (1): 65–71. doi: 10.1093/ehjcvp/pvu020
98. Pizzi C., Manfrini O., Fontana F., Bugiardini R.: Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity. Circulation. 2004; 109 (1): 53–58. doi: 10.1161/01.CIR.0000100722.34034.E4
99. Chen J.W., Hsu N.W., Wu T.C., Lin S.J., Chang M.S.: Long-term angiotensin-converting enzyme inhibition reduces plasma asymmetric dimethylarginine and improves endothelial nitric oxide bioavailability and coronary microvascular function in patients with syndrome X. Am J Cardiol. 2002; 90 (9): 974–982. doi: 10.1016/S0002-9149 (02)02664-4
100. Pauly D.F., Johnson B.D., Anderson R.D., et al.: In women with symptoms of cardiac ischemia, nonobstructive coronary arteries, and microvascular dysfunction, angiotensin-converting enzyme inhibition is associated with improved microvascular function. Am Heart J. 2011; 162 (4): 678–684. doi: 10.1016/j.ahj.2011.07.011
101. Kayikcioglu M., Payzin S., Yavuzgil O., Kultursay H., Can L.H., Soydan I.: Benefits of statin treatment in cardiac syndrome-X1. Eur Heart J. 2003; 24 (22): 1999–2005. doi: 10.1016/S0195-668X (03)00478-0
102. Fábián E., Varga A., Picano E., Vajo Z., Rónaszéki A., Csanády M.: Effect of simvastatin on endothelial function in cardiac syndrome X patients. Am J Cardiol. 2004; 94 (5): 652–655. doi: 10.1016/j.amjcard.2004.05.035
103. Mehta P.K., Goykhman P., Thomson L.E.J., et al.: Ranolazine improves angina in women with evidence of myocardial ischemia but no obstructive coronary artery disease. JACC Cardiovasc Imaging. 2011; 4 (5): 514–522. doi: 10.1016/j.jcmg.2011.03.007
104. Tagliamonte E., Rigo F., Cirillo T., et al.: Effects of ranolazine on noninvasive coronary flow reserve in patients with myocardial ischemia but without obstructive coronary artery disease. Echocardiography. 2015; 32 (3): 516–521. doi: 10.1111/echo.12674
105. Villano A., Di Franco A., Nerla R., et al.: Effects of ivabradine and ranolazine in patients with microvascular angina pectoris. Am J Cardiol. 2013; 112 (1): 8–13. doi: 10.1016/j.amjcard.2013.02.045
106. Chen J.W., Lee W.L., Hsu N.W., et al.: Effects of short-term treatment of Nicorandil on exercise- induced myocardial ischemia and abnormal cardiac autonomic activity in microvascular angina. Am J Cardiol. 1997; 80 (1): 32–38. doi: 10.1016/S0002-9149 (97)00279-8
107. Nalbantgil S., Altintiğ A., Yilmaz H., Nalbantgil I., Önder R.: The effect of trimetazidine in the treatment of microvascular angina. Int J Angiol. 1999; 8 (1): 40–43. doi: 10.1007/BF01616842
108. Adamson D.L., Webb C.M., Collins P.: Esterified estrogens combined with methyltestosterone improve emotional well-being in postmenopausal women with chest pain and normal coronary angiograms. Menopause. 2001; 8 (4): 233–238. doi: 10.1097/00042192-200107000-00003
109. Emdin M., Picano E., Lattanzi F., l’Abbate A.: Improved exercise capacity with acute aminophylline administration in patients with syndrome X. J Am Coll Cardiol. 1989; 14 (6): 1450–1453. doi: 10.1016/0735-1097 (89)90380-X
110. Yoshio H., Shimizu M., Kita Y., et al.: Effects of short-term aminophylline administration on cardiac functional reserve in patients with syndrome X. J Am Coll Cardiol. 1995; 25 (7): 1547–1551. doi: 10.1016/0735-1097 (95)00097-N
111. Elliott P.M., Krzyzowska-Dickinson K., Calvino R., Hann C., Kaski J.C.: Effect of oral aminophylline in patients with angina and normal coronary arteriograms (cardiac syndrome X). Heart. 1997; 77 (6): 523–526. doi: 10.1136/hrt.77.6.523
112. Fukumoto Y., Mohri M., Inokuchi K., et al.: Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol. 2007; 49 (3): 117–121. doi: 10.1097/FJC.0b013e31802ef532
113. Mohri M., Shimokawa H., Hirakawa Y., Masumoto A., Takeshita A.: Rho-kinase inhibition with intracoronary fasudil prevents myocardial ischemia in patients with coronary microvascular spasm. J Am Coll Cardiol. 2003; 41 (1): 15–19. doi: 10.1016/S0735-1097 (02)02632-3
114. Olgin J.E., Takahashi T., Wilson E., Vereckei A., Steinberg H., Zipes D.P.: Effects of Thoracic Spinal Cord Stimulation on Cardiac Autonomic Regulation of the Sinus and Atrioventricular Nodes. J Cardiovasc Electrophysiol. 2002; 13: 475–481.
115. Hautvast R.W.M., Blanksma P.K., DeJongste M.J.L., et al.: Effect of spinal cord stimulation on myocardial blood flow assessed by positron emission tomography in patients with refractory angina pectoris. Am J Cardiol. 1996; 77 (7): 462–467. doi: 10.1016/S0002-9149 (97)89338-1
116. Murray S., Carson K.G.S., Ewings P.D., Collins P.D., James M.A.: Spinal cord stimulation significantly decreases the need for acute hospital admission for chest pain in patients with refractory angina pectoris. Heart. 1999; 82 (1): 89 LP-92. doi: 10.1136/hrt.82.1.89
117. Sharma U., Ramsey H.K., Tak T.: The role of enhanced external counter pulsation therapy in clinical practice. Clin Med Res. 2013; 11 (4): 226–232. doi: 10.3121/cmr.2013.1169

Date

2022.01.10

Type

Contents

Identifier

ISSN 0015-5616

Details

Title

Journal title

Yearbook

Volume

Issue

Divisions of PAS

Publisher

Bibliography

Date

Type

Identifier